Authors
Latest:
Relapsed/Refractory Multiple Myeloma: Future Directions in CareClosing out their discussion on bispecifics in multiple myeloma, expert hematologist-oncologists share practical advice for community physicians alongside their hopes for the future.
Latest:
Impairment-Driven Cancer Rehabilitation Improves Survivors' Quality of LifeThe lack of comprehensive rehabilitation services is a profound source of unnecessary suffering for survivors.
Latest:
Dr Phillips on the Shifting Treatment Paradigm For CAR T-Cell Therapy in LBCLAdrienne Phillips, MD, MPH, discusses the impact of CAR T-cell therapy on the treatment paradigm for patients with large B-cell lymphoma, highlighting key advancements in the decision-making process for CAR T-cell therapy selection.
Latest:
Dr. Ribeiro on the Role of Surgery in Pancreatic CancerAfonso Ribeiro, MD, discusses the role of surgery in treating patients with pancreatic cancer.
Latest:
Dr. Barzi on Combination Regorafenib and Pembrolizumab in MSS CRCAfsaneh Barzi, MD, PhD, discusses the combination of regorafenib and pembrolizumab in patients with microsatellite stable colorectal cancer.
Latest:
Ã…ge Schultz, DVM, PhD, Discusses the Cost of Supportive Care MedicineÃ…ge Schultz, DVM, PhD, executive director, Multinational Association of Supportive Care in Cancer (MASCC), discusses pain management and the cost of supportive care medicine.
Latest:
Dr. Paner on HORIZON Trial in Multiple MyelomaAgne Paner, MD, director, discusses the phase II HORIZON trial in relapsed/refractory multiple myeloma.
Latest:
Dr. Janus on the Role of Moxetumomab Pasudotox in Hairy Cell LeukemiaAgnieszka Janus, MD, PhD, discusses the efficacy and safety of moxetumomab pasudotox as a treatment option for patients with hairy cell leukemia. This agent was approved by the FDA in September 2018 for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy, including a purine nucleoside analog.
Latest:
Novel Agents Signal Progress in the Management of Platinum-Resistant Ovarian CancerThe evaluation of noncytotoxic agents for the treatment of epithelial ovarian cancer has produced encouraging findings in recent months, which has led to the approval of new agents with novel mechanisms of action and continuing studies into many more potential therapies.
Latest:
It's Time to Tackle the Evidence Gap in Lymphoid CancersAlthough CLL is the most common chronic leukemia, there remains no single agreed-upon standard of care for first-line treatment.
Latest:
Dr. Tarhini on Recent Practice-Changing Clinical Trials in MelanomaAhmad Tarhini, MD, PhD, director, Melanoma and Skin Cancer Program, Center for Immuno-Oncology Research, Cleveland Clinic, discusses some recent practice-changing clinical trials in melanoma.
Latest:
TRT in Patients With Prostate Cancer on Active Surveillance: Are We Really Putting Gas on Fire?Investigators hypothesized that testosterone replacement does not have a negative impact on the oncologic outcomes of treatment-naive patients with prostate cancer on surveillance and they performed a retrospective review of an institutional active surveillance prostate cancer database.
Latest:
Dr. Galal on Managing AEs Linked With CAR T-Cell TherapyAhmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the management of adverse events (AEs) associated with CAR T-cell therapy.
Latest:
Dr. Al-Niaimi Discusses Cytoreductive Surgery in Ovarian CancerAhmed N. Al-Niaimi, MD, assistant professor of obstetrics and gynecology, University of Wisconsin School of Medicine and Public Health, discusses cytoreductive surgery in ovarian cancer.
Latest:
Dr Kaseb on the Investigation of Adjuvant Atezolizumab and Bevacizumab in Early-Stage HCCAhmed O. Kaseb, MD, discusses the significance of results from the phase 3 IMbrave050 trial of adjuvant atezolizumab and bevacizumab for patients with early-stage hepatocellular carcinoma.
Latest:
Dr. Dogan on Updated WHO Classifications in DLBCLAhmet Dogan, MD, PhD, chief of Hematopathology Service, Departments of Pathology and Laboratory Medicine at Memorial Sloan Kettering Cancer Center, discusses the updated World Health Organization (WHO) classification and how it impacts treatment decisions for patients with diffuse large B-cell lymphoma (DLBCL).
Latest:
NOW Initiative: Payer & Provider Collaborations in Oncology Benefits ManagementPayers recognize the need to expand benefits management for oncology but struggle to find effective solutions amid the complexity of available therapies and skepticism from oncologists, who are facing their own set of economic pressures. The National Oncology Working Group (NOW) Initiative is trying to change the sometimes adversarial relationship between payers and oncologists through a collaborative model.
Latest:
Dr. He on the Results of the LEGACY Study Examining Y-90 in HCCRuth Aiwu He, MD, PhD, discusses the results of the LEGACY study in patients with hepatocellular carcinoma.
Latest:
Dr He on the Evaluation of Camrelizumab Plus Rivoceranib in Unresectable HCCAiwu Ruth He, MD, PhD, discusses the evaluation of camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.
Latest:
Improving Care in Multiple Myeloma: Unmet Needs and Future DirectionsClosing out their discussion on novel agents in multiple myeloma, expert panelists consider remaining unmet needs and future evolutions in the treatment paradigm.
Latest:
Dr Chari on the Selection of BCMA-Targeted Therapies Within Multiple MyelomaAjai Chari, MD, discusses important patient factors to consider when selecting between currently approved BCMA-targeted therapies for the treatment of patients with multiple myeloma.
Latest:
Dr Chari on the MonumenTAL-1 Trial Examining Talquetamab in Multiple MyelomaAjay Chari, MD, discusses findings from the phase 1/2 MonumenTAL-1 trial investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.
Latest:
Dr Nooka on the Utility of Iopofosine I 131 in Waldenström MacroglobulinemiaAjay K. Nooka, MD, MPH, FACP, discusses the CLOVER-WaM trial of iopofosine I 131 for heavily pretreated, refractory Waldenström macroglobulinemia.
Latest:
CNS and Dose-Reduction Events After Abiraterone/Prednisone in mCRPCAjay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with prostate cancer following treatment with abiraterone acetate (Zytiga) plus prednisone.
Latest:
New Strategy Boosts Microenvironment to Promote Antitumor Immunity in GI MetastasesDespite the promise of immunotherapy for treating patients with advanced cancers, the success of using such therapies for progressive gastrointestinal malignancies such as colorectal liver metastases (CRLM) has been limited so far.
